Navigation

Breast cancer (early) - docetaxel: costing template and report

A costing report and costing template have been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA109 - Docetaxel for the adjuvant treatment of early node-positive breast cancer.

The costing report focuses on the financial impact of the key factors in this technical appraisal for England. The report has been prepared in consultation with the technical leads and has been approved for publication by the Institute. It should be noted that the cost and activity assessments in the report are estimates based on a number of assumptions. These assessments provide an indication of the likely impact of the principal recommendations and are not absolute figures.

As part of this work, a costing template has been developed to provide health communities with the ability to assess the likely local impact of the principal recommendations in the appraisal based on their population. Other assumptions can be altered to better reflect local circumstances.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 27 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.